DexCom’s continuous glucose monitor
This article was originally published in The Gray Sheet
DexCom plans a limited launch of Seven, its next-generation, seven-day STS continuous glucose monitor, at the end of the second quarter followed by a "more robust launch" in the third quarter, the company announces May 31 upon the device's FDA approval. The original STS continuous monitor was approved in March 2006, requiring glucose sensors to be replaced every three days (1"The Gray Sheet" May 22, 2006, p. 17). DexCom says it will hold a conference call "to discuss the approval and product launch plans in more detail at a later date"...
You may also be interested in...
Dexcom plans to submit a PMA supplement for its seven-day STS continuous glucose monitoring system by the end of June
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.